Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

M Zibelman; ER Plimack

doi:10.21037/atm.2019.04.57

Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

Research output: Contribution to journal › Editorial

Original language	American English
Article number	S95
Pages (from-to)	S95
Number of pages	4
Journal	Annals of Translational Medicine
Volume	7
Issue number	Suppl 3
DOIs	https://doi.org/10.21037/atm.2019.04.57
State	Published - Jul 2019

Access to Document

10.21037/atm.2019.04.57

Cite this

@article{113842e0a5bc4865ab46ca42556d3bb3,

title = "Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?",

author = "M Zibelman and ER Plimack",

year = "2019",

month = jul,

doi = "10.21037/atm.2019.04.57",

language = "American English",

volume = "7",

pages = "S95",

journal = "Annals of Translational Medicine",

issn = "2305-5839",

publisher = "AME Publishing Company",

number = "Suppl 3",

}

TY - JOUR

T1 - Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma

T2 - take new drugs but keep the old?

AU - Zibelman, M

AU - Plimack, ER

PY - 2019/7

Y1 - 2019/7

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000483693200021&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.21037/atm.2019.04.57

DO - 10.21037/atm.2019.04.57

M3 - Editorial

C2 - 31576303

SN - 2305-5839

VL - 7

SP - S95

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

IS - Suppl 3

M1 - S95

ER -

Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

Access to Document

Other files and links

Fingerprint

Cite this